• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服塞拉菌素治疗犬泛发性蠕形螨病。

Oral selamectin in the treatment of canine generalised demodicosis.

机构信息

Small Animal Medical Clinic, Ludwig Maximilian University, Veterinärstrasse 13, 80539 Munich, Germany.

出版信息

Vet Rec. 2010 Jun 5;166(23):710-4. doi: 10.1136/vr.4850.

DOI:10.1136/vr.4850
PMID:20525946
Abstract

The success rates and adverse effects of a selamectin spot-on preparation, given orally weekly or every other week, against canine generalised demodicosis were evaluated in 44 dogs, 39 with juvenile-onset demodicosis and five with adult-onset demodicosis. The dogs received selamectin at a dose of 24 to 48 mg/kg once a week, or the same dose every two weeks. Thirty-eight dogs completed the study, four dogs were lost to follow-up and two dogs died. Nine dogs went into remission: all had the juvenile-onset form of the disease. There was no difference between the two treatment groups, but dogs with clinical scores of 65 or less responded significantly better than those with a score of over 65 (P=0.0015). The most frequent adverse effects were vomiting and diarrhoea. Two dogs exhibited mild reversible neurological side effects, which resolved with cessation of treatment. Difficulties in oral administration were observed in several dogs.

摘要

评估了每周或每两周口服一剂塞拉菌素点眼剂治疗犬全身性蠕形螨病的成功率和不良反应。44 只犬接受了 24 至 48 毫克/千克的塞拉菌素剂量,每周一次或每两周一次。38 只狗完成了研究,4 只狗失访,2 只狗死亡。9 只狗缓解:均为幼年发病形式。两组治疗无差异,但临床评分 65 分或以下的狗比评分超过 65 分的狗反应明显更好(P=0.0015)。最常见的不良反应是呕吐和腹泻。两只狗出现轻度可逆的神经副作用,停药后消失。几只狗在口服给药时遇到困难。

相似文献

1
Oral selamectin in the treatment of canine generalised demodicosis.口服塞拉菌素治疗犬泛发性蠕形螨病。
Vet Rec. 2010 Jun 5;166(23):710-4. doi: 10.1136/vr.4850.
2
Canine generalized demodicosis treated with varying doses of a 2.5% moxidectin+10% imidacloprid spot-on and oral ivermectin: parasiticidal effects and long-term treatment outcomes.用不同剂量的2.5%莫西菌素+10%吡虫啉滴剂和口服伊维菌素治疗犬全身性蠕形螨病:杀虫效果和长期治疗结果
Vet Parasitol. 2014 Oct 15;205(3-4):687-96. doi: 10.1016/j.vetpar.2014.08.021. Epub 2014 Sep 4.
3
Efficacy of weekly oral doramectin treatment in canine demodicosis.每周口服多拉菌素治疗犬蠕形螨病的疗效
Vet Rec. 2010 Jul 10;167(2):63-4. doi: 10.1136/vr.b4885.
4
Treatment of canine generalized demodicosis with a 'spot-on' formulation containing 10% moxidectin and 2.5% imidacloprid (Advocate, Bayer Healthcare).使用含有10%莫西菌素和2.5%吡虫啉的“滴剂”制剂(拜耳保健公司的Advocate)治疗犬全身性蠕形螨病。
Vet Dermatol. 2009 Oct;20(5-6):441-6. doi: 10.1111/j.1365-3164.2009.00790.x.
5
Ivermectin for treatment of generalized demodicosis in dogs.伊维菌素治疗犬全身性蠕形螨病
J Am Vet Med Assoc. 1995 Nov 15;207(10):1308-10.
6
Efficacy of selamectin in the treatment of canine cheyletiellosis.塞拉菌素治疗犬蠕形螨病的疗效。
Vet Rec. 2002;151(25):773.
7
Treatment of canine-generalized demodicosis: a blind, randomized clinical trial comparing the efficacy of Advocate(Bayer Animal Health) with ivermectin.犬全身性蠕形螨病的治疗:一项比较拜宠爽(拜耳动物保健公司)与伊维菌素疗效的盲法随机临床试验。
Vet Dermatol. 2009 Oct;20(5-6):447-55. doi: 10.1111/j.1365-3164.2009.00803.x.
8
Doramectin in the treatment of generalized demodicosis.多拉菌素治疗全身性蠕形螨病
Vet Dermatol. 2018 Apr;29(2):104-e41. doi: 10.1111/vde.12515. Epub 2017 Dec 29.
9
Efficacy of selamectin in the treatment of nasal mite (Pneumonyssoides caninum) infection in dogs.塞拉菌素治疗犬鼻螨(犬肺刺螨)感染的疗效。
J Am Anim Hosp Assoc. 2004 Sep-Oct;40(5):400-4. doi: 10.5326/0400400.
10
Efficacy of selamectin in the treatment of cheyletiellosis in pet rabbits.塞拉菌素治疗宠物兔疥螨病的疗效
Vet Dermatol. 2008 Feb;19(1):26-7. doi: 10.1111/j.1365-3164.2007.00629.x.

引用本文的文献

1
Juvenile-onset and adult-onset demodicosis in dogs in the UK: prevalence and breed associations.英国犬类的幼年型和成年型蠕形螨病:患病率及品种关联
J Small Anim Pract. 2020 Jan;61(1):32-41. doi: 10.1111/jsap.13067. Epub 2019 Oct 4.